Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: A pilot study

Amalia S. Lehmann, Jamie Renbarger, Catherine L. McCormick, Ariel R. Topletz, Carrie Rouse, David Haas

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Nausea and vomiting of pregnancy (NVP) is a common condition. The objective of this study was to evaluate the association between response to antiemetics in the treatment of NVP and genetic polymorphisms in the serotonin receptor subunit genes HTR3A and HTR3B.Methods: Pregnant women ≥18 years of age with NVP starting antiemetic therapy with promethazine, prochlorperazine, metoclopramide, or ondansetron at ≤ 16 weeks gestational age were eligible. The study recruited 29 women with complete data and sampling who returned for their one week follow-up and were genotyped for HTR3A and HTR3B polymorphisms. Severity of NVP was captured (using Pregnancy Unique Quantification of Emesis (PUQE) and Quality of Life (QOL) tools) upon enrollment and after one week of antiemetic therapy. These measures were correlated with pharmacogenetic variability.Results: Subjects with genotype associated with high serotonin affinity of the 5-HT3B receptor (rs1176744, CC) required more antiemetic medications (p < 0.001) than other subjects. Those with genotypes associated with increased expression of the 5-HT3A receptor subunit (rs1062613, CT or TT) had worse final PUQE scores (p = 0.01) than other subjects while rs3782025 variants carriers had significantly better initial (p = 0.02) and final (p = 0.02) PUQE scores than other subjects.Conclusions: HTR3B and HTR3A gene variants may contribute to variability in response to antiemetic therapy for NVP.

Original languageEnglish
Article number132
JournalBMC Pregnancy and Childbirth
Volume13
DOIs
StatePublished - Jun 20 2013

Fingerprint

Antiemetics
Pharmacogenetics
Nausea
Vomiting
Pregnancy
Therapeutics
Prochlorperazine
Genotype
Promethazine
Receptors, Serotonin, 5-HT3
Ondansetron
Metoclopramide
Serotonin Receptors
Genetic Polymorphisms
Genes
Gestational Age
Pregnant Women
Quality of Life

Keywords

  • Antiemetics
  • Nausea and vomiting of pregnancy
  • Pharmacogenomics
  • Pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy : A pilot study. / Lehmann, Amalia S.; Renbarger, Jamie; McCormick, Catherine L.; Topletz, Ariel R.; Rouse, Carrie; Haas, David.

In: BMC Pregnancy and Childbirth, Vol. 13, 132, 20.06.2013.

Research output: Contribution to journalArticle

@article{61b95274412d41d19443bcb36ca7c499,
title = "Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: A pilot study",
abstract = "Background: Nausea and vomiting of pregnancy (NVP) is a common condition. The objective of this study was to evaluate the association between response to antiemetics in the treatment of NVP and genetic polymorphisms in the serotonin receptor subunit genes HTR3A and HTR3B.Methods: Pregnant women ≥18 years of age with NVP starting antiemetic therapy with promethazine, prochlorperazine, metoclopramide, or ondansetron at ≤ 16 weeks gestational age were eligible. The study recruited 29 women with complete data and sampling who returned for their one week follow-up and were genotyped for HTR3A and HTR3B polymorphisms. Severity of NVP was captured (using Pregnancy Unique Quantification of Emesis (PUQE) and Quality of Life (QOL) tools) upon enrollment and after one week of antiemetic therapy. These measures were correlated with pharmacogenetic variability.Results: Subjects with genotype associated with high serotonin affinity of the 5-HT3B receptor (rs1176744, CC) required more antiemetic medications (p < 0.001) than other subjects. Those with genotypes associated with increased expression of the 5-HT3A receptor subunit (rs1062613, CT or TT) had worse final PUQE scores (p = 0.01) than other subjects while rs3782025 variants carriers had significantly better initial (p = 0.02) and final (p = 0.02) PUQE scores than other subjects.Conclusions: HTR3B and HTR3A gene variants may contribute to variability in response to antiemetic therapy for NVP.",
keywords = "Antiemetics, Nausea and vomiting of pregnancy, Pharmacogenomics, Pregnancy",
author = "Lehmann, {Amalia S.} and Jamie Renbarger and McCormick, {Catherine L.} and Topletz, {Ariel R.} and Carrie Rouse and David Haas",
year = "2013",
month = "6",
day = "20",
doi = "10.1186/1471-2393-13-132",
language = "English",
volume = "13",
journal = "BMC Pregnancy and Childbirth",
issn = "1471-2393",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy

T2 - A pilot study

AU - Lehmann, Amalia S.

AU - Renbarger, Jamie

AU - McCormick, Catherine L.

AU - Topletz, Ariel R.

AU - Rouse, Carrie

AU - Haas, David

PY - 2013/6/20

Y1 - 2013/6/20

N2 - Background: Nausea and vomiting of pregnancy (NVP) is a common condition. The objective of this study was to evaluate the association between response to antiemetics in the treatment of NVP and genetic polymorphisms in the serotonin receptor subunit genes HTR3A and HTR3B.Methods: Pregnant women ≥18 years of age with NVP starting antiemetic therapy with promethazine, prochlorperazine, metoclopramide, or ondansetron at ≤ 16 weeks gestational age were eligible. The study recruited 29 women with complete data and sampling who returned for their one week follow-up and were genotyped for HTR3A and HTR3B polymorphisms. Severity of NVP was captured (using Pregnancy Unique Quantification of Emesis (PUQE) and Quality of Life (QOL) tools) upon enrollment and after one week of antiemetic therapy. These measures were correlated with pharmacogenetic variability.Results: Subjects with genotype associated with high serotonin affinity of the 5-HT3B receptor (rs1176744, CC) required more antiemetic medications (p < 0.001) than other subjects. Those with genotypes associated with increased expression of the 5-HT3A receptor subunit (rs1062613, CT or TT) had worse final PUQE scores (p = 0.01) than other subjects while rs3782025 variants carriers had significantly better initial (p = 0.02) and final (p = 0.02) PUQE scores than other subjects.Conclusions: HTR3B and HTR3A gene variants may contribute to variability in response to antiemetic therapy for NVP.

AB - Background: Nausea and vomiting of pregnancy (NVP) is a common condition. The objective of this study was to evaluate the association between response to antiemetics in the treatment of NVP and genetic polymorphisms in the serotonin receptor subunit genes HTR3A and HTR3B.Methods: Pregnant women ≥18 years of age with NVP starting antiemetic therapy with promethazine, prochlorperazine, metoclopramide, or ondansetron at ≤ 16 weeks gestational age were eligible. The study recruited 29 women with complete data and sampling who returned for their one week follow-up and were genotyped for HTR3A and HTR3B polymorphisms. Severity of NVP was captured (using Pregnancy Unique Quantification of Emesis (PUQE) and Quality of Life (QOL) tools) upon enrollment and after one week of antiemetic therapy. These measures were correlated with pharmacogenetic variability.Results: Subjects with genotype associated with high serotonin affinity of the 5-HT3B receptor (rs1176744, CC) required more antiemetic medications (p < 0.001) than other subjects. Those with genotypes associated with increased expression of the 5-HT3A receptor subunit (rs1062613, CT or TT) had worse final PUQE scores (p = 0.01) than other subjects while rs3782025 variants carriers had significantly better initial (p = 0.02) and final (p = 0.02) PUQE scores than other subjects.Conclusions: HTR3B and HTR3A gene variants may contribute to variability in response to antiemetic therapy for NVP.

KW - Antiemetics

KW - Nausea and vomiting of pregnancy

KW - Pharmacogenomics

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84879071939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879071939&partnerID=8YFLogxK

U2 - 10.1186/1471-2393-13-132

DO - 10.1186/1471-2393-13-132

M3 - Article

C2 - 23786674

AN - SCOPUS:84879071939

VL - 13

JO - BMC Pregnancy and Childbirth

JF - BMC Pregnancy and Childbirth

SN - 1471-2393

M1 - 132

ER -